<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Cancer Center

Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs

minute read

by Traders Union News | July 24, 2026
placeholder

Inhibrx Biosciences is intensifying its research into chondrosarcoma, a rare bone cancer, as patients continue to face limited treatment choices.

Topics: Press Coverage

Related Articles

About Us

Members

Research

Leadership

Newsroom

Give Now

Cancer Resources

Cancers We Treat

Second Opinions

Multidisciplinary Clinics

Cancer Screening

Clinical Trials

Affiliates

CU Anschutz

CU School of Medicine

CU Skaggs School of Pharmacy

Colorado School of Public Health

CU Boulder

Flint Animal Cancer Center

Clinical Partners

UCHealth

Children's Hospital Colorado

Veterans Affairs Medical Center

Denver Health

National Jewish Health

© 2025  The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.